These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25707916)

  • 21. Stochastic Model of the Adaptive Immune Response Predicts Disease Severity and Captures Enhanced Cross-Reactivity in Natural Dengue Infections.
    Nguyen HD; Chaudhury S; Waickman AT; Friberg H; Currier JR; Wallqvist A
    Front Immunol; 2021; 12():696755. PubMed ID: 34484195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-enhanced infection of monocytes as the pathogenetic mechanism for severe dengue illness.
    Kliks S
    AIDS Res Hum Retroviruses; 1990 Aug; 6(8):993-8. PubMed ID: 2223245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage.
    Lin CF; Lei HY; Shiau AL; Liu CC; Liu HS; Yeh TM; Chen SH; Lin YS
    J Med Virol; 2003 Jan; 69(1):82-90. PubMed ID: 12436482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoimmune pathogenesis in dengue virus infection.
    Lin CF; Wan SW; Cheng HJ; Lei HY; Lin YS
    Viral Immunol; 2006; 19(2):127-32. PubMed ID: 16817755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune response to dengue virus and prospects for a vaccine.
    Murphy BR; Whitehead SS
    Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virus antibody dynamics in primary and secondary dengue infections.
    Gujarati TP; Ambika G
    J Math Biol; 2014 Dec; 69(6-7):1773-800. PubMed ID: 24384697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention.
    Goncalvez AP; Engle RE; St Claire M; Purcell RH; Lai CJ
    Proc Natl Acad Sci U S A; 2007 May; 104(22):9422-7. PubMed ID: 17517625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection.
    Laoprasopwattana K; Libraty DH; Endy TP; Nisalak A; Chunsuttiwat S; Vaughn DW; Reed G; Ennis FA; Rothman AL; Green S
    J Infect Dis; 2005 Aug; 192(3):510-9. PubMed ID: 15995967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Formation of infectious dengue virus-antibody immune complex in vivo in marmosets (Callithrix jacchus) after passive transfer of anti-dengue virus monoclonal antibodies and infection with dengue virus.
    Moi ML; Ami Y; Shirai K; Lim CK; Suzaki Y; Saito Y; Kitaura K; Saijo M; Suzuki R; Kurane I; Takasaki T
    Am J Trop Med Hyg; 2015 Feb; 92(2):370-6. PubMed ID: 25548383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus.
    Ito M; Mukai RZ; Takasaki T; Kotaki A; Kurane I
    Arch Virol; 2010 Oct; 155(10):1617-24. PubMed ID: 20644969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies determine virulence in dengue.
    Halstead SB
    Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E48-56. PubMed ID: 19751402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-dependent enhancement of heterotypic dengue infections involved in suppression of IFNgamma production.
    Yang KD; Yeh WT; Yang MY; Chen RF; Shaio MF
    J Med Virol; 2001 Feb; 63(2):150-7. PubMed ID: 11170052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent progress in dengue vaccine research and development.
    Miller N
    Curr Opin Mol Ther; 2010 Feb; 12(1):31-8. PubMed ID: 20140814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay.
    Hadjilaou A; Green AM; Coloma J; Harris E
    J Immunol; 2015 Oct; 195(7):3490-6. PubMed ID: 26320246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to dengue fever--the good, the bad, and the ugly?
    Schmidt AC
    N Engl J Med; 2010 Jul; 363(5):484-7. PubMed ID: 20818870
    [No Abstract]   [Full Text] [Related]  

  • 37. Dengue hemorrhagic fever with special emphasis on immunopathogenesis.
    Kurane I
    Comp Immunol Microbiol Infect Dis; 2007 Sep; 30(5-6):329-40. PubMed ID: 17645944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.
    Wang Y; Si L; Luo Y; Guo X; Zhou J; Fang D; Yan H; Zeng G; Jiang L
    Appl Microbiol Biotechnol; 2015 Nov; 99(22):9685-98. PubMed ID: 26219500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dengue virus isolation by antibody-dependent enhancement of infectivity in macrophages.
    Cardosa MJ
    Lancet; 1987 Jan; 1(8526):193-4. PubMed ID: 2880019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-Cell mediated adaptive immunity and antibody-dependent enhancement in secondary dengue infection.
    Sasmal SK; Takeuchi Y; Nakaoka S
    J Theor Biol; 2019 Jun; 470():50-63. PubMed ID: 30878699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.